<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01544972</url>
  </required_header>
  <id_info>
    <org_study_id>ZTB170212</org_study_id>
    <nct_id>NCT01544972</nct_id>
  </id_info>
  <brief_title>Serum Level Measurement of Oral Paracetamol and Oral Ibuprofen for Patent Ductus Arteriosus Treatment in Preterm Infants</brief_title>
  <official_title>Serum Level Measurement of Oral Paracetamol and Oral Ibuprofen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zekai Tahir Burak Women's Health Research and Education Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zekai Tahir Burak Women's Health Research and Education Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine oral paracetamol and ibuprofen efficacy and safety
      in relation to serum levels in closure of patent ductus arteriosus in preterm infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine oral paracetamol and ibuprofen efficacy and safety in relation to serum levels
      in closure of patent ductus arteriosus in preterm infants.

      Eighty preterm infants with patent ductus arteriosus will be enrolled in this
      prospective-randomized study. Patients will receive oral ibuprofen at an initial dose of 10
      mg/kg, followed by 5 mg/kg at 24 and 48 h or oral paracetamol 15 mg/kg per dose every 6 hours
      for 3 days.

      One of the following echocardiographic criteria of a duct size &gt; 1.5 mm, a left
      atrium-to-aorta ratio &gt; 1.5, left-to-right shunting of blood, end diastolic reversal of blood
      flow in the aorta, or poor cardiac function in addition signs of patent ductus arteriosis
      determined the need of treatment.

      Three consecutive blood sample from infants for 3 days before dose application of
      drugs(ibuprofen and paracetamol will be obtained.

      The relation of pharmacokinetics of drugs to drug response will be evaluated
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To detection of safe and effective serum levels of paracetamol and ibuprofen in preterm infants treated for PDA</measure>
    <time_frame>up to 6 months</time_frame>
    <description>The measurement of Serum levels of Paracetamol and Ibuprofen in preterm infants treated with Oral Paracetamol and Oral Ibuprofen.
To determine of effective serum levels of paracetamol and ibuprofen for treatment of patent ductus arteriosus in preterm infants.
In normally, effective and safely dose of NSAIDs for treatment of PDA are exactly unknown. Therefore we will detected cut-off serum levels for effective, safely and hazardous.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Patent Ductus Arteriosus</condition>
  <arm_group>
    <arm_group_label>Oral paracetamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral paracetamol</intervention_name>
    <description>Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours.</description>
    <arm_group_label>Oral paracetamol</arm_group_label>
    <other_name>Calpol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral ibuprofen</intervention_name>
    <description>Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.</description>
    <arm_group_label>Oral ibuprofen</arm_group_label>
    <other_name>Pedifen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Birth weight below 1250 gram

          -  Diagnosed patent ductus arteriosus by Echocardiographic examination

        Exclusion Criteria:

          -  Accompanied other congenital cardiac anomalies

          -  Severe thrombocytopenia &lt; 60.000

          -  Severe intracranial bleeding (Grade III - IV)

          -  Intestinal abnormality and necrotising enterocolitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>10 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sadık Yurttutan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zekai Tahir Burak Women's Health Research and Education Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sadık Yurttutan, MD</last_name>
    <email>sdkyurttutan@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mehmet Yekta Oncel, MD</last_name>
    <email>dryekta@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zekai Tahir Burak Maternity Teaching Hospital, Division of Neonatology</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ugur Dilmen, Professor</last_name>
      <email>ugurdilmen@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Omer Erdeve, As.Prof</last_name>
      <email>omererdeve@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sadık Yurttutan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2012</study_first_submitted>
  <study_first_submitted_qc>March 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2012</study_first_posted>
  <last_update_submitted>December 13, 2012</last_update_submitted>
  <last_update_submitted_qc>December 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zekai Tahir Burak Women's Health Research and Education Hospital</investigator_affiliation>
    <investigator_full_name>Sadik Yurttutan</investigator_full_name>
    <investigator_title>Zekai Tahir Burak Maternity and Teaching Hospital</investigator_title>
  </responsible_party>
  <keyword>Patent Ductus Arteriosus</keyword>
  <keyword>Paracetamol</keyword>
  <keyword>Ibuprofen</keyword>
  <keyword>Serum levels</keyword>
  <keyword>Preterm infant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ductus Arteriosus, Patent</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

